Assessing risk in pulmonary arterial hypertension: what we know, what we don't
Eur Respir J
.
2017 Aug 3;50(2):1701353.
doi: 10.1183/13993003.01353-2017.
Print 2017 Aug.
Authors
Raymond L Benza
1
,
Harrison W Farber
2
,
Mona Selej
3
4
,
Mardi Gomberg-Maitland
5
Affiliations
1
Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, PA, USA RBENZA@wpahs.org.
2
Pulmonary and Critical Care, Boston Medical Center, Boston, MA, USA.
3
University of California San Francisco, Dept of Medicine, Cardiology, Pulmonary Hypertension Clinic, San Francisco, CA, USA.
4
Actelion Pharmaceuticals US, Inc., South San Francisco, CA, USA.
5
Cardiology, Heart and Vascular Institute, Falls Church, VA, USA.
PMID:
28775053
DOI:
10.1183/13993003.01353-2017
No abstract available
Publication types
Editorial
Comment
MeSH terms
Familial Primary Pulmonary Hypertension*
Humans
Hypertension, Pulmonary*
Risk Factors